Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer
The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass a wide range of therapies, including androgen deprivation therapy (ADT), novel hormonal therapy (NHT), PARP inhibitors (PARPi), immunotherapy, nuclear medicine therapy, and localized treatments.